Lantheus Confirmed The Company And Its Subsidiary Were Sued By Advanced Accelerator Applications, Novartis Unit For Patent Infringement For Abbreviated New Drug Application For Lutetium Lu 177 Dotatate, Generic Version Of Lutathera - 8K
Portfolio Pulse from Benzinga Newsdesk
Lantheus Holdings, Inc. and its subsidiary are facing a lawsuit from Advanced Accelerator Applications, a Novartis AG unit, for patent infringement. The lawsuit concerns an Abbreviated New Drug Application (ANDA) filed for a generic version of Lutathera, known as Lutetium Lu 177 Dotatate, which is used to treat certain neuroendocrine tumors.
January 26, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lantheus Holdings is being sued for patent infringement related to its generic drug application for Lutetium Lu 177 Dotatate, which could impact its business operations and financials.
The lawsuit for patent infringement could lead to legal costs, potential damages, and an injunction against selling the generic drug, which would negatively affect Lantheus' financials and stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Novartis AG, through its unit Advanced Accelerator Applications, is suing Lantheus Holdings for patent infringement, which could protect its drug Lutathera from generic competition.
The lawsuit aims to protect Novartis' revenue from Lutathera by preventing generic competition. If successful, it could maintain the drug's market exclusivity, positively impacting Novartis' short-term revenue and stock price.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 70